Jianfeng Group Lin2016 -026 (Announcement on Foreign Investment of Subsidists)
Release time:
2020-08-05
证券代码:600668 证券简称:尖峰集团 公告编号:2016-026
债券简称:13尖峰01 债券代码:122227
债券简称:13尖峰02 债券代码:122344
浙江尖峰集团股份有限公司
关于子公司对外投资的公告
本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏,并对其内容的真实性、准确性和完整性承担个别及连带责任。
重要内容提示:
l 本公司控股子公司浙江尖峰药业有限公司与德国葛芙制药有限公司、珠海横琴德运嘉国际贸易有限公司签订了《中外合资经营企业合同》,拟在中国浙江省金华市共同出资设立一家中外合资经营企业,致力于建成一个婴幼儿、儿童用药的制药企业。
l 尖峰药业本次拟出资人民币1100万元,占合营公司注册资本的55%。
l 合营公司的成立尚需相关政府商务部门的批准;合营公司成立后的运营团队组织与磨合、产品研发、产品上市销售情况等事项都存在一定的不确定性风险。
一、对外投资概述
(一)2016年7月12日,本公司控股子公司浙江尖峰药业有限公司(以下简称:尖峰药业)与德国葛芙制药有限公司(以下简称:葛芙制药)、珠海横琴德运嘉国际贸易有限公司(以下简称:德运嘉)签订了《中外合资经营企业合同》,合营各方根据平等互利的原则和长期真诚合作的愿望,努力吸取各自专长和采用适宜的先进技术以及科学的管理方法成立合营公司,并致力于建成一个以婴幼儿、儿童用药制剂研发、生产和销售为主的现代化制药企业。
合营公司中文名称是:浙江金得尔儿婴药品有限公司(以下简称“合营公司”)(以工商行政管理部门核定的名称为准)。合营公司的注册资本为人民币2000万元,其中:尖峰药业以现金人民币1100万元出资,葛芙制药以专有技术的知识产权评估作价人民币500万元出资,德运嘉以现金人民币400万元出资。合营公司拟注册在中国浙江省金华市金西开发区。
(二)本次对外投资,尖峰药业的出资金额为人民币1100万元,根据本公司《章程》有关规定,在董事长对外投资审批权限范围之内,无需提交公司董事会、股东大会审议。
(三)该合作事项不属于关联交易,也不构成《上市公司重大资产重组管理办法》规定的重大资产重组情况。
二、协议主题的基本情况
(一)德国葛芙制药有限公司
1、企业名称:德国葛芙制药有限公司(GOHOFF ARZNEIMITTEL GmbH)
2、企业性质:有限责任公司
3、注册地:德国柏林
4、注册日期:2016年3月24日
5、主要办公地点:德国柏林茵塞尔路17号
6、法定代表人:Katharina Bodmeier
7、注册资本:25000欧元
8、主营业务:药品、化学品、化妆品和保健品的开发、销售和贸易
9、主要股东:
|
序号 |
股东名称或姓名 |
出资额(欧元) |
出资比例 |
|
1 |
Prof.Dr.Roland Bodmeier |
12500 |
50% |
|
2 |
FangHuang |
11250 |
45% |
|
3 |
Katharina Bodmeier |
1250 |
5% |
(二)珠海横琴德运嘉国际贸易有限公司
1、企业名称:珠海横琴德运嘉国际贸易有限公司
2、企业性质:有限责任公司(自然人独资)
3、注册地:珠海市横琴新区
4、注册日期:2015年06月17日
5、主要办公地点:珠海市横琴新区宝华路6号105室-3754
6、法定代表人:李华智
7、注册资本:500万元人民币,截止公告日实收资本为240万元。
8、主营业务:从事货物与技术的进出口业务;贸易咨询、技术咨询、技术服务;化妆品及卫生用品进出口批发和零售;非许可类医疗器械经营;医疗用品和器材进出口批发和零售;草药和天然产品的进出口批发和零售;保健食品、乳制品进出口批发和零售;动物用健康食品、保健品和药品的进出口批发和零售;药品进出口批发和零售;预包装食品的批发和销售。
9、主要股东:李华智先生占公司注册资本100%。
10、主要财务指标:截止2015年12月31日,德运嘉的资产总额为27.35万元、资产净额5.93万元、营业收入48.54万元、净利润-4.07万元等;
三、合营公司的基本情况
1、企业名称:浙江金得尔儿婴药品有限公司(以工商行政管理部门核定的名称为准)
2、经营范围:保健品和药品进出口,研究、开发、生产和销售婴幼儿用药及其他生物及化学医药产品。
3、注册资本:2000万元人民币
4、出资方式:尖峰药业以现金出资人民币1100万元,占注册资本的55%;葛芙制药以“地西泮栓”、“对乙酰氨基酚栓”两项专有技术评估作价人民币500万元出资,占注册资本的25%;德运嘉以现金出资人民币400万元出资,占注册资本的20%。
5、董事会安排:合营公司董事会由5名董事组成,尖峰药业委派3人,葛芙制药委派1人,德运嘉委派1人。董事长由尖峰药业委派担任,副董事长由葛芙制药委派。董事长、副董事长和董事的任职期限应为四年。
6、管理层安排:合营公司设总经理1名和财务经理1名。总经理由葛芙制药委派,财务经理由尖峰药业委派,任期为四年。
7、无形资产出资情况:葛芙制药以其拥有的“地西泮栓”、“对乙酰氨基酚栓”两项专有技术作价500万元人民币进行出资。金华金辰资产评估有限公司对上述两项专有技术进行评估并出具了《评估报告》,评估价值为555.00万元(大写人民币伍佰伍拾伍万元)。葛芙制药所拥有的“地西泮栓”、“对乙酰氨基酚栓”两项专有技术不存在抵押、质押或者其他重大争议、诉讼或仲裁事项、查封或者冻结等司法措施。
地西泮栓是用于抗焦虑、睡眠障碍,增加肌肉张力的治疗药物;对乙酰氨基酚是用于感冒或感冒引起的发热,也用于缓解轻至中度疼痛。“地西泮栓”、“对乙酰氨基酚栓”都已经在德国上市。中国国家食品药品监督管理总局的网站显示已经有54个“对乙酰氨基酚栓”的批准文号;尚未有“地西泮栓”的批准文号, 但“地西泮”片剂、注射剂已经有较多的批准文号。合资公司成立后将以上述两项专有技术为基础进行相应产品的研发、经营。
四、合同的主要内容
2016年7月12日,尖峰药业(甲方)、葛芙制药(乙方)和德运嘉(丙方)签订了《中外合资经营企业合同》,主要条款有:
1、甲方、乙方和丙方三方将根据《中华人民共和国中外合资经营企业法》、《中华人民共和国中外合资经营企业法实施条例》等其他与本合同相关的法律、法规和规定,按照平等互利的原则,通过友好协商,一致同意在中国浙江省金华市共同设立中外合资经营企业。
2、合营公司注册资本为人民币2000万元。甲方出资额占注册资本的55%,其中以现金出资人民币1100万元。乙方出资额占注册资本的25%,其中以知识产权出资,以评估作价出资人民币500万元。丙方出资额占注册资本的20%,其中以现金出资人民币400万元。
3、以现金出资时,甲、丙双方应于2017年6月30日前缴付认缴的出资;以知识产权出资时,乙方应在公司成立之日起180工作日内,办理知识产权变更登记,将出资用知识产权所有权和使用权转移至合营公司。
4、合营公司租用甲方拥有的位于金华金西开发区尖峰药业制药基地内厂房。甲方同意该场地可用以建成合营公司的药品研发、生产基地。场地租金须不高于市场价,租赁协议另行签订。租赁期限应为中国法律允许的最长期限20年。
5、董事会是合营公司最高权力机构,合营公司的营业执照颁发之日为其董事会成立之日。合营公司的重大事项应由董事会全体一致决定。对于下列事项应由董事会全体董事一致通过方可做出决定:(1)合营企业章程的修改;(2)合营企业的中止、提前终止、解散、清算或延长合营公司期限;(3)合营企业注册资本的增加和减少;(4)合营企业的合并和分立;(5)合营各方向合营公司外的其他方转让股权。
除上述条款外的其它事项应由多数票通过决议决定,但是至少乙方或丙方委派的一名董事投了赞成票。
6、合营公司设总经理1 名和财务经理1 名。总经理应由乙方委派,财务经理应由甲方委派。他们的任期为四年,同样可根据董事会的决定连任。合营公司的其他高层管理人员,由总经理提议,董事会批准后聘请。
7、合营公司的合营期限为30年,从合营公司营业执照签发之日开始。
8、若合资公司决定解散,需进行清算。在制定和执行清算方案的过程中,清算委员会应尽可能将合营公司的产品、产品开发权益、知识产权、专有技术等分配给乙方和/或丙方。
9、除因不可抗力外,若本合同一方在实质性方面不完整、不恰当履行或终止履行本合同,在收到合营其他方通知后六十天内仍不纠正其违约行为时,该方便构成违约,违约方应承担责任,负责赔偿履约方或合营公司由此遭受的损失,赔偿上限不超过认缴的出资额或以非货币财产出资时的非货币财产。
10、本合同的效力,解释,执行,修改,终止及争议的解决,应适用中国法律。已公布的中国法律未涉及事宜,采用国际惯例。
11、在履行本合同及附件过程中发生的一切争议,各方首先应友好协商解决,如争议各方不能协商解决,则经各方书面同意,可将争议提交中国国际经济贸易仲裁委员会按其仲裁程序进行仲裁。仲裁语言采用中文,翻译成英文。仲裁裁决是终局的,并对各方均有约束力。
12、本合同自合营各方签字盖章,并经有权的审批机构批准后生效。
五、对公司的影响
随着我国人口政策的调整,“全面二胎”政策的实施,预计婴幼儿用药市场将迎来快速增长的机遇,本次尖峰药业通过组建合营公司,引进德国技术开发婴幼儿用药,符合公司的发展战略规划,是公司做大做强医药业务的具体实施。
六、可能存在的风险
本次签署的是《中外合资经营企业合同》,合营公司的成立尚需相关政府商务部门的批准;合营公司成立后的运营团队组织与磨合、产品研发、产品上市销售情况等事项都存在一定的不确定性风险。
敬请广大投资者注意投资风险。
特此公告
浙江尖峰集团股份有限公司董事会
二〇一六年七月十二日
More information
Pharmaceutical Company Established New Drug R & D Promotion Committee
Recently, the new drug research and development promotion committee of Jianfeng pharmaceutical company was formally established, which will be responsible for promoting the new drug research and development progress of pharmaceutical companies and subordinate enterprises, and coordinating the new drug research and development work of various departments and subordinate enterprises. The New Drug Promotion Committee is headed by Huang Jinlong, deputy general manager of the group and general manager of the pharmaceutical company, and Jiang Hong, deputy general manager of the pharmaceutical company, is headed by Pang Xiong, Shi Cunyuan, Xu Lizhen, Yu Jingjing, Zheng Kunwu, Feng Lixiang, Kang Litao, Li Qian, Wu Chonggui, Zhai Tsunami, Huang Fang and Tong Xiaojun. The committee has an office, and Shi Cunyuan is also the director of the office, responsible for the supervision, communication, and coordination of the company's new drug research and development projects. The main responsibilities of the new drug promotion committee include: organizing the establishment and improvement of the R & D project management system and relevant regulations of the pharmaceutical company; organizing the formulation of the development plan of the new drug R & D project of the pharmaceutical company and supervising the implementation; making decisions on project initiation and participating in project evaluation; supervising the management of new drug R & D of the pharmaceutical company and providing guidance; Responsible for the process management of new drug R & D projects and the promotion and coordination of new drug R & D; carry out the assessment of new drug research and development projects; issue the responsibility system assessment and task statement of new drug research and development projects; be responsible for solving major technical problems in the process of new drug research and development; be responsible for the research and improvement of the management mode of research and development projects of pharmaceutical companies; be responsible for the future trend analysis of new drug research and development projects; review the major scientific research achievements of pharmaceutical companies and put forward reward suggestions. Huang Jinlong said that the research and development of new drugs is an important foundation for the healthy development of the pharmaceutical industry and is a systematic project. Jianfeng Pharmaceutical has always attached great importance to the research and development of new drugs, but there is still a certain gap between the progress of research and development and the development process of the enterprise, and the lack of coordination in the research and development process also affects the progress and quality of new drug research and development to a certain extent. The purpose of the establishment of the New Drug Research and Development Promotion Committee is to solve the progress of new drug research and development, to find and solve problems in time, to implement more targeted, and to effectively integrate enterprise resources, improve the speed and quality of new drug research and development, and make good product reserves for the healthy development of pharmaceutical companies. (Reporter Ni Yingzhen)
2020
09-11
Jianfeng Pharmaceutical ranks among the top 100 Chinese pharmaceutical industries in 2019
On August 25, the "2019 Top 100 Series List of China's Pharmaceutical Industry" was released in Kunming. Zhejiang Jianfeng Pharmaceutical Company was shortlisted as one of the top 100 enterprises in China's pharmaceutical industry. The product Berunning (Olopatadine Hydrochloride Eye Drops) was selected as the "Most Growing Product Brand" of China's pharmaceutical industry ". The "Top 100 Pharmaceutical Industry Series List" was evaluated and released by Guangzhou Punctuation Pharmaceutical Information Co., Ltd., a subsidiary of the Southern Institute of Pharmaceutical Economics of the State Drug Administration, and is known as the "Oscar in Chinese Pharmaceutical Industry. Southern Institute is the earliest institution in China that specializes in pharmaceutical industry policy and market economy research, pharmaceutical market research, pharmaceutical economic data analysis and research, and pharmaceutical professional media publishing. It is in the field of market information value-added services and media communication and marketing services in China's pharmaceutical and health industry., The field of professional quality improvement has extremely extensive influence. The "Top 100 Pharmaceutical Industry" is comprehensively evaluated by the company's annual pharmaceutical industry sales revenue, total profit and R & D investment results. On the same day, the "most growing product brand" of Chinese medicine selected by the Southern Institute's media "Pharmaceutical Economic News" was released simultaneously. Spike Pharmaceuticals product Beirunning (Olopatadine Hydrochloride Eye Drops) was selected. (Xu Yuting)
2020
09-01
Company Disclosure 2020 Semi-Annual Report
On August 28, the Group held the 16th meeting of the 10th Board of Directors of the Company by means of communication, and considered and adopted the "2020 Semi-Annual Report of Jianfeng Group" and the "Proposal on Changes in the Company's Accounting Policy". On August 29, the Company's 2020 semi-annual report was publicly disclosed on the Shanghai Stock Exchange and the Shanghai Securities News and China Securities News. In the first half of the year, the Group focused on the general policy of "grasping projects, making up for shortcomings, improving quality and efficiency, and constantly improving the core competitive advantage", and on the basis of doing a good job in epidemic prevention and control, the Group seized the resumption of work and production, accelerated project construction, and enhanced the core competitiveness of enterprises. In the first half of 2020, the company achieved total operating income of 1.44 billion yuan, net profit attributable to shareholders of 0.368 billion yuan, net profit per share of 1.07 yuan. As of the end of June 2020, the Company's total assets were $5.892 billion, net assets were $4.068 billion, and net assets per share were $11.82. From February to April, affected by the epidemic, the national project construction progress slowed down, cement market demand decreased; after May, the epidemic was effectively controlled, infrastructure investment continued to recover, the real estate industry continued to pick up, cement sales steadily rebounded. During the outbreak, Daye Peak completed the technical transformation projects such as the cold machine, cement mill, into the desulfurization tower anti-corrosion transformation, to ensure the efficient operation of the production equipment after the resumption of work. Yunnan peak rotary kiln production, cement production and other major technical and economic indicators of steady rise; comply with market trends, timely adjustment of marketing policies. Guizhou Jianfeng has promoted the project infrastructure construction, equipment installation and commissioning, raw material bidding and other work in an orderly manner, and through preliminary publicity to enhance the popularity of the Jianfeng brand in the local area, and make a series of preparations for the transformation from project construction to production and operation. In the first half of 2020, the reform of China's medical and health system continued to deepen, and new policies were introduced intensively. Peak Pharmaceuticals and its subsidiaries in the epidemic prevention work at the same time in the first time to achieve the resumption of production, and actively organize donations to support the fight against the epidemic, was named the annual "war epidemic star" the most socially responsible pharmaceutical enterprises. In the first half of the year, Jianfeng Pharmaceutical continued to increase the introduction and development of varieties, and JFAN-1001 applied for clinical application of new anti-tumor drugs. At present, it has obtained the notice of approval for clinical trials. Optimize the production process of API workshop and further shorten the production cycle of raw materials. Continue to improve product sales policies and strengthen market channel control. Shanghai North Carolina further straightened out the internal management structure, production and marketing convergence more smoothly, continue to promote the construction of Anhui North Carolina and Anhui Zhongwang Phase II technical transformation project, promote the peak pharmaceutical raw materials, preparations integration of industrial upgrading strategy. Other business segments of the company actively responded to the challenge of the new crown epidemic and carried out production and operation activities in a standardized and orderly manner. Tianjin natural products company vigorously explore the international and domestic markets, sales revenue to achieve steady growth. Peak Health focuses on the basic idea of "sales orientation, burden reduction and efficiency improvement, fine-grained savings, cost reduction and efficiency enhancement" to effectively improve the operational efficiency of enterprises. Jianfeng International Trade has actively developed new storage business varieties and achieved practical results, and has become the first enterprise in Jinhua to formally obtain the qualification of "network freight. Peak cable seizes the special needs of communication cables such as subways, vigorously promotes large logarithmic cables for subways, and strives to achieve the long tail effect. On the same day, the company also held the 10th meeting of the Ninth Board of Supervisors and reviewed and approved relevant reports. (residual fruit)
2020
09-01
The company organizes new employee induction training
From August 12 to 14, in order to strengthen the training of talents in the group and improve the comprehensive quality of new employees, Jiang Xiaomeng, secretary of the party committee and chairman of the group company, Yu Jianhong, general manager, and other leaders and heads of relevant enterprises and departments conducted a three-day induction training for new employees. New employees from foreign enterprises such as Guizhou Huangping Peak, Daye Peak and Shanghai North Carolina participated simultaneously through online methods. In the course of corporate culture, General Manager Yu Jianhong started from the history of the development and struggle of the peak, divided into five stages: hard work, determined reform, diversified development, strategic adjustment, and strategic development, and introduced in detail the development process of the group company and the current industrial layout., The results achieved; from the aspects of enterprise spirit, vision, development philosophy, values, business philosophy, etc, this paper introduces the peak corporate culture rooted in 62 years of history and inherited in the blood; from the perspective of an enterprise manager and old employees, he speaks a lot of truth to the new employees and puts forward a lot of hopes and suggestions. Chairman Jiang Xiaomeng took "How New Employees Achieve Win-Win with Enterprises" as the topic, and proposed that the key to the success of an enterprise lies in how to select, retain, educate and employ people. Peak and employees complement each other. Peak can achieve today's achievements and the struggle of generations of peak people are inseparable. He also taught new employees the basic concepts that need to be understood, the basic qualities that need to be possessed and the sense of hardship in entering the new environment through 16 key words, and combined with his own experience and quoting from others, he analyzed the core elements of success, the signs of a successful career, the personal qualities that need to be possessed for success, and the importance of establishing a personal knowledge management system, it expresses the ardent hope of new employees to adjust their mentality, keep learning, clear goals, clear dreams, cultivate win-win thinking, and grow up together with the peak. The heads of the human resources department of the group company, the safety management office of the group company, and the comprehensive department of the pharmaceutical company also taught the new employees the corporate rules and regulations and the "Employee Handbook", safety knowledge and professional ethics. The new employees also visited the group exhibition hall and had a deeper understanding of the development history and enterprise achievements of the peak. After the training, the human resources department also organized an examination to test the training effect. (Reporter Chen Shengmu)
2020
08-21
According to this newspaper, through the interconnection monitoring of the transportation department in Zhejiang province, the network freight platform of peak international trading company passed the online service capability audit, interface access audit, eight capability identification and other audit procedures, and successfully obtained the road transportation business license with the qualification of "network freight" on July 2. It is understood that Jianfeng International Trade is currently the first enterprise in Jinhua and Quzhou to obtain this qualification.
2020
08-05
News from our newspaper On July 21, Xi Jinping, General Secretary of the Central Committee of the Communist Party of China, President of the State, and Chairman of the Central Military Commission hosted a symposium for entrepreneurs in Beijing and delivered an important speech. Over the past few days, the General Secretary's speech has aroused strong repercussions in all walks of life. On July 23, Jiang Xiaomeng, chairman of the group company, said in an interview with Jinhua TV that the general secretary's speech was calm and inspiring, and pointed out the direction of future work for entrepreneurs.
2020
08-05